ESMO updates precision oncology framework to improve targeted therapies
ESMO has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), a major update to the internationally recognized precision oncology framework that helps oncologists assess the clinical relevance of molecular alterations and match patients with the most appropriate targeted therapies.
Read original article on The Medical News →Related news
-
Q&A: Expert explains why women should reconsider skipping the Pap smear
United Kingdom
-
'Molecular glue' stabilizes protein that inhibits development of non–small cell lung cancer and uterine cancer
United Kingdom
-
Male breast cancer: Risk rises with age, expert explains
United Kingdom
-
MRI scans and DNA data uncover new genetic links to fatty liver disease
United Kingdom
-
A brain-computer interface may give unresponsive ICU patients a voice
United Kingdom
-
Large-scale meteorological patterns linked to Ebola virus outbreaks
United Kingdom
-
Researchers develop cognitive testing app for at-home use
United Kingdom
-
ESMO introduces new set of principles to strengthen the communication of cancer research
United Kingdom